From the Faculdade de Medicina (L.M.C.), Universidade Salvador, Salvador, Brazil.
Serviço de Clínica Médica (P.C.T.M.L.), Hospital Santo Antônio, Associação Obras Sociais Irmã Dulce, Salvador, Brazil.
AJNR Am J Neuroradiol. 2021 Dec;42(12):2119-2126. doi: 10.3174/ajnr.A7303. Epub 2021 Oct 21.
In the field of interventional neuroradiology, antiplatelet agents are commonly used to prepare patients before the implantation of permanent endovascular materials. Among the available drugs, clopidogrel is the most frequently used one, but resistance phenomena are considered to be relatively common. Prasugrel and ticagrelor were recently added to the pharmacologic arsenal, but the safety of these agents in patients undergoing neurointerventional procedures is still a subject of discussion. The cumulative experience with both drugs is less extensive than that with clopidogrel, and the experience with patients in the neurology field is less extensive than in the cardiology domain. In the present article, we provide a narrative review of studies that investigated safety issues of oral P2Y12 inhibitors in interventional neuroradiology and discuss potential routes for future research.
在介入神经放射学领域,抗血小板药物通常用于在植入永久性血管内材料之前对患者进行准备。在可用的药物中,氯吡格雷是最常用的一种,但耐药现象被认为相对常见。普拉格雷和替格瑞洛最近被添加到药物武器库中,但这些药物在接受神经介入治疗的患者中的安全性仍然是一个讨论的话题。这两种药物的累积经验都不如氯吡格雷广泛,而在神经病学领域的经验也不如心脏病学领域广泛。在本文中,我们对研究口服 P2Y12 抑制剂在介入神经放射学中的安全性问题的研究进行了叙述性综述,并讨论了未来研究的潜在途径。